[The biochemical markers of bone remodeling in cancer patients with skeletal involvement].
The report discusses a study of pyridinoline (Pyd) and deoxypyridinoline (Dpyd) as biochemical markers of bone resorption as well as total bone alkaline phosphatase level (APh) and that of its bone fraction as criteria of osteogenesis in skeletal lesions in breast, prostate and lung cancer and multiple myeloma. The investigation established a significantly enhanced Pyd and Dpyd excretion with urine and increased blood-serum APh levels in skeletal cancers (n = 271) as compared with healthy subjects (n = 173) and patients without bone metastases (n = 94). A case has been made for determination of total excretion of Pyd crosslinks of collagen to diagnose bone metastases. Most pronounced hyperenzymemia was found in prostate cancer which points to the leading role of APh as a bone metastasis marker. Pyd and Dpyd excretion and APh levels were significantly higher among patients multiple metastases with than in those with single bone metastases. The universality of pyridinoline crosslinks as skeletal damage markers has been confirmed by establishing a significant correlation between drug and therapeutic effect for Pyd and Dpyd only, in patients receiving ibandronate.
Liubimova
N V
NV
N. N. Blokhin Center for Oncology Research, Russian Academy of Medical Sciences, Moscow.
Bronnikov
I Iu
IIu
Robins
S P
SP
Trapeznikova
M F
MF
Kushlinskiĭ
N E
NE
D000135:Acid Phosphatase / Q000097:blood; D000596:Amino Acids / Q000652:urine*; D014408:Biomarkers, Tumor / Q000652:urine*; D001859:Bone Neoplasms / Q000175:diagnosis / Q000556:secondary* / Q000652:urine*; D016723:Bone Remodeling / Q000502:physiology*; D001842:Bone and Bones / Q000201:enzymology; D004796:Clinical Enzyme Tests; D005260:Female; D006801:Humans; D008297:Male; D009369:Neoplasms / Q000652:urine*; D010024:Osteoporosis / Q000652:urine; D012016:Reference Values
D000596:Amino Acids; D014408:Biomarkers, Tumor; C015484:pyridinoline; C036020:deoxypyridinoline; D000135:Acid Phosphatase